Detalhe da pesquisa
1.
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer.
Front Oncol
; 13: 1175617, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228496
2.
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells.
Cancers (Basel)
; 15(16)2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627156